Profiel
Frank L.
Porfido held the position of Chief Financial Officer at Tyme Technologies, Inc. in 2021 and Vice President-Finance at UroGen Pharma, Inc. from 2019 to 2021.
He earned an MBA from Fairleigh Dickinson University and an undergraduate degree from Pace University.
Eerdere bekende functies van Frank L. Porfido
| Bedrijven | Functie | Einde |
|---|---|---|
| TYME TECHNOLOGIES, INC. | Director of Finance/CFO | 16-09-2022 |
| UroGen Pharma, Inc. | Corporate Officer/Principal | 01-05-2021 |
Opleiding van Frank L. Porfido
| Fairleigh Dickinson University | Masters Business Admin |
| Pace University | Undergraduate Degree |
Ervaring
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Connecties
Eerstegraads connecties
Bedrijven verbonden in de eerste graad
Man
Vrouw
Besturend
Uitvoerend
Verwante bedrijven
| Bedrijven in privébezit | 2 |
|---|---|
Tyme Technologies, Inc.
 Tyme Technologies, Inc. Pharmaceuticals: MajorHealth Technology Tyme Technologies, Inc. operates as a biotechnology company, which engages in the development and commercialization of cancer therapies. It offers a clinical program named SM-88 which is a novel, oral, and monotherapy investigational agent that aims to disrupt the cancer cell's protein synthesis. The company was founded by Steve Hoffman and Michael Demurjian on November 22, 2011 and is headquartered in Bedminster, NJ. | Health Technology |
| UroGen Pharma, Inc. | Health Technology |
